Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland.

While exponential modeling of PASI, BSA, and DLQI trajectories suggested a higher probability of achieving complete clearance with bimekizumab, these differences did not reach statistical significance at the common endpoint of week 12.

also in 111,027 other papers